Akero Therapeutics, Inc. financial data

Symbol
AKRO on Nasdaq
Location
601 Gateway Boulevard, Suite 350, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.58K % -34.7%
Debt-to-equity 7.31 % -17%
Return On Equity -30.7 % +5.66%
Return On Assets -28.6 % +4.32%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 82.3M shares +17.9%
Common Stock, Shares, Outstanding 80.1M shares +15.1%
Entity Public Float 1.57B USD -37.7%
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 82M shares +18.1%
Weighted Average Number of Shares Outstanding, Diluted 82M shares +18.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 287M USD +23.9%
General and Administrative Expense 43M USD +14.2%
Operating Income (Loss) -330M USD -22.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -293M USD -23.4%
Earnings Per Share, Basic -3 USD/shares +1.32%
Earnings Per Share, Diluted -3 USD/shares +1.32%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 176M USD -44.3%
Marketable Securities, Current 562M USD +40%
Cash, Cash Equivalents, and Short-term Investments 988M USD +25.6%
Assets, Current 755M USD +1.02%
Property, Plant and Equipment, Net 15K USD -25%
Operating Lease, Right-of-Use Asset 552K USD -32.7%
Other Assets, Noncurrent 108K USD -76.9%
Assets 1.01B USD +23%
Accounts Payable, Current 20.4M USD -19.1%
Employee-related Liabilities, Current 4.98M USD +13.9%
Liabilities, Current 47.7M USD +10.1%
Operating Lease, Liability, Noncurrent 289K USD -52.2%
Liabilities 47.9M USD -39.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.83M USD -13.2%
Retained Earnings (Accumulated Deficit) -1.05B USD -38.7%
Stockholders' Equity Attributable to Parent 958M USD +29.7%
Liabilities and Equity 1.01B USD +23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -67.7M USD -92.6%
Net Cash Provided by (Used in) Financing Activities 396M USD +7.79%
Net Cash Provided by (Used in) Investing Activities -482M USD -934%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 80.1M shares +15.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 176M USD -44.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 980K USD +27.6%
Deferred Tax Assets, Valuation Allowance 242M USD +36.5%
Deferred Tax Assets, Gross 249M USD +38.5%
Operating Lease, Liability 605K USD -31.9%
Depreciation 1K USD -90.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -293M USD -24.9%
Lessee, Operating Lease, Liability, to be Paid 646K USD -34.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 208K USD -40.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 351K USD +2.93%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 41K USD -57.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 208K USD -40.7%
Deferred Tax Assets, Operating Loss Carryforwards 116M USD +31.2%
Unrecognized Tax Benefits 5.89M USD +73.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 208K USD -40.7%
Operating Lease, Payments 333K USD +2.78%
Additional Paid in Capital 1.5B USD +43.9%
Deferred Tax Assets, Net of Valuation Allowance 7.19M USD +168%
Share-based Payment Arrangement, Expense 34.3M USD +19.7%
Interest Expense 4.62M USD +5.8%